泊沙康唑在免疫抑制小鼠模型中对毛霉属真菌的体内活性。
In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.
作者信息
Sun Qiu N, Najvar Laura K, Bocanegra Rosie, Loebenberg David, Graybill John R
机构信息
Division of Infectious Disease, Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229-3900, USA.
出版信息
Antimicrob Agents Chemother. 2002 Jul;46(7):2310-2. doi: 10.1128/AAC.46.7.2310-2312.2002.
Abstract
The in vivo activities of posaconazole, itraconazole, and amphotericin B in neutropenic mice with zygomycosis were compared. The in vitro MICs of posaconazole and itraconazole for the strains of Mucor spp. used in this study ranged from 0.125 to 8 microg/ml and 0.25 to 8 microg/ml, respectively. The in vitro MIC range for amphotericin B is 0.125 to 0.25 microg/ml. At twice-daily doses of >or=15 mg/kg of body weight, posaconazole prolonged the survival of the mice and reduced tissue burden.
摘要
比较了泊沙康唑、伊曲康唑和两性霉素B在中性粒细胞减少的接合菌病小鼠模型中的体内活性。本研究中所用毛霉属菌株对泊沙康唑和伊曲康唑的体外最低抑菌浓度（MIC）分别为0.125至8微克/毫升和0.25至8微克/毫升。两性霉素B的体外MIC范围为0.125至0.25微克/毫升。当每日两次给予≥15毫克/千克体重的剂量时，泊沙康唑可延长小鼠存活时间并减轻组织负荷。
相似文献
1
In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.泊沙康唑在免疫抑制小鼠模型中对毛霉属真菌的体内活性。
Antimicrob Agents Chemother. 2002 Jul;46(7):2310-2. doi: 10.1128/AAC.46.7.2310-2312.2002.
2
In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole.泊沙康唑与两性霉素 B 在体外和体内对环孢菌属毛霉菌属侵袭性感染的活性比较：泊沙康唑疗效不佳。
Antimicrob Agents Chemother. 2012 May;56(5):2246-50. doi: 10.1128/AAC.05956-11. Epub 2012 Jan 30.
3
Drug combinations against Mucor irregularis in vitro.抗不规则毛霉的药物组合的体外研究。
Antimicrob Agents Chemother. 2013 Jul;57(7):3395-7. doi: 10.1128/AAC.02612-12. Epub 2013 Apr 15.
4
A Revised Species Concept for Opportunistic Species Reveals Species-Specific Antifungal Susceptibility Profiles.机会性致病物种的修订物种概念揭示了特定物种的抗真菌药敏谱。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00653-19. Print 2019 Aug.
5
Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.泊沙康唑在侵袭性肺曲霉病和毛霉病中性粒细胞减少小鼠模型中的比较药效学。
Antimicrob Agents Chemother. 2014 Nov;58(11):6767-72. doi: 10.1128/AAC.03569-14. Epub 2014 Sep 2.
6
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.泊沙康唑、雷夫康唑和伏立康唑与伊曲康唑及两性霉素B相比，对239株曲霉属及其他丝状真菌临床分离株的抗真菌活性：2000年SENTRY抗菌监测项目报告
Antimicrob Agents Chemother. 2002 Apr;46(4):1032-7. doi: 10.1128/AAC.46.4.1032-1037.2002.
7
Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.泊沙康唑、伏立康唑、伊曲康唑和两性霉素B对曲霉和根霉的体外活性比较以及根霉的协同试验。
Med Mycol. 2008 Sep;46(6):567-73. doi: 10.1080/13693780801975576.
8
Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.异曲康唑和米卡芬净单药或联合治疗小鼠毛霉菌病
J Antimicrob Chemother. 2017 Feb;72(2):462-466. doi: 10.1093/jac/dkw433. Epub 2016 Oct 24.
9
Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales.多中心评估最小抑菌浓度（MIC）分布以确定流行病学临界值，用于检测毛霉目中最具临床相关性的菌种对两性霉素B、泊沙康唑和伊曲康唑的耐药性。
Antimicrob Agents Chemother. 2015 Mar;59(3):1745-50. doi: 10.1128/AAC.04435-14. Epub 2015 Jan 12.
10
Galleria mellonella as a model system to study virulence potential of mucormycetes and evaluation of antifungal treatment.黄粉虫作为研究毛霉菌毒力潜能及抗真菌治疗评估的模型系统。
Med Mycol. 2019 Apr 1;57(3):351-362. doi: 10.1093/mmy/myy042.
引用本文的文献
1
Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents.毛霉菌病：真菌感染的隐藏谜团，可能的诊断、治疗和新治疗药物的研发。
Eur J Med Chem. 2023 Jan 15;246:115010. doi: 10.1016/j.ejmech.2022.115010. Epub 2022 Dec 10.
2
Evaluation of Sex Differences in Murine Diabetic Ketoacidosis and Neutropenic Models of Invasive Mucormycosis.小鼠糖尿病酮症酸中毒和侵袭性毛霉菌病中性粒细胞减少模型中的性别差异评估
J Fungi (Basel). 2021 Apr 18;7(4):313. doi: 10.3390/jof7040313.
3
High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections.高剂量泊沙康唑治疗唑类耐药曲霉菌病和其他难治疗的霉菌感染。
Mycoses. 2020 Feb;63(2):122-130. doi: 10.1111/myc.13028. Epub 2019 Dec 15.
4
Posaconazole: An Update of Its Clinical Use.泊沙康唑：临床应用最新进展
Pharmacy (Basel). 2015 Oct 21;3(4):210-268. doi: 10.3390/pharmacy3040210.
5
Facial nerve paralysis: A case report of rare complication in uncontrolled diabetic patient with mucormycosis.面神经麻痹：一例未控制的糖尿病合并毛霉菌病患者罕见并发症的病例报告。
J Nat Sci Biol Med. 2015 Jan-Jun;6(1):226-8. doi: 10.4103/0976-9668.149195.
6
Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales.多中心评估最小抑菌浓度（MIC）分布以确定流行病学临界值，用于检测毛霉目中最具临床相关性的菌种对两性霉素B、泊沙康唑和伊曲康唑的耐药性。
Antimicrob Agents Chemother. 2015 Mar;59(3):1745-50. doi: 10.1128/AAC.04435-14. Epub 2015 Jan 12.
7
Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.泊沙康唑在侵袭性肺曲霉病和毛霉病中性粒细胞减少小鼠模型中的比较药效学。
Antimicrob Agents Chemother. 2014 Nov;58(11):6767-72. doi: 10.1128/AAC.03569-14. Epub 2014 Sep 2.
8
Mucormycosis in an HIV-infected renal transplant patient: A case report and review of the literature.一名感染人类免疫缺陷病毒的肾移植患者的毛霉菌病：病例报告及文献综述
Am J Case Rep. 2014 Feb 15;15:74-8. doi: 10.12659/AJCR.890026. eCollection 2014.
9
Locked-in syndrome after basilary artery thrombosis by mucormycosis masquerading as meningoencephalitis in a lymphoma patient.一名淋巴瘤患者因毛霉菌病导致基底动脉血栓形成后出现闭锁综合征，最初表现为脑膜脑炎。
Ecancermedicalscience. 2013 Dec 19;7:382. doi: 10.3332/ecancer.2013.382. eCollection 2013.
10
Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections.艾沙康唑概况及其在治疗严重侵袭性真菌感染中的潜力。
Infect Drug Resist. 2013 Oct 22;6:163-74. doi: 10.2147/IDR.S51340.
本文引用的文献
1
Phycomycosis. A clinicopathologic study of fifty-one cases.藻菌病。51例临床病理研究。
Lab Invest. 1962 Nov;11:963-85.
2
In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole.接合菌纲临床分离株对两性霉素B、氟胞嘧啶、伊曲康唑和伏立康唑的体外敏感性
J Antimicrob Chemother. 2001 Dec;48(6):919-21. doi: 10.1093/jac/48.6.919.
3
Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole.用两性霉素B和伊曲康唑治疗小鼠犁头霉感染。
J Antimicrob Chemother. 2001 Oct;48(4):583-6. doi: 10.1093/jac/48.4.583.
4
Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion.两性霉素B胶体分散体治疗21例侵袭性毛霉病
Eur J Clin Microbiol Infect Dis. 2001 Jul;20(7):460-6. doi: 10.1007/s100960100528.
5
Cluster of pulmonary infections caused by Cunninghamella bertholletiae in immunocompromised patients.柏氏小克银汉霉引起的免疫功能低下患者肺部感染群
Clin Infect Dis. 2000 Oct;31(4):910-3. doi: 10.1086/318144. Epub 2000 Oct 11.
6
Therapeutic experience with fluconazole in the treatment of fungal infections in diabetic patients.氟康唑治疗糖尿病患者真菌感染的治疗经验。
Mycoses. 1999;42 Suppl 2:97-100.
7
Zygomycosis in the 1990s in a tertiary-care cancer center.20世纪90年代一家三级护理癌症中心的接合菌病。
Clin Infect Dis. 2000 Jun;30(6):851-6. doi: 10.1086/313803. Epub 2000 Jun 13.
8
Zygomycetes in human disease.人类疾病中的接合菌纲真菌。
Clin Microbiol Rev. 2000 Apr;13(2):236-301. doi: 10.1128/CMR.13.2.236.
9
Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.新型三唑类药物SCH56592与棘白菌素类药物MK-0991（L-743,872）和LY303366对机会性丝状真菌、双相真菌和酵母的体外活性比较。
J Clin Microbiol. 1998 Oct;36(10):2950-6. doi: 10.1128/JCM.36.10.2950-2956.1998.
10
Rhinocerebral zygomycosis.
Mycoses. 1998 Jan-Feb;41(1-2):51-3. doi: 10.1111/j.1439-0507.1998.tb00376.x.
Zotero 插件